Latest Asx Quotation News

Impact Minerals (ASX: IPT) has pushed back the deadline for its $4.13 million renounceable rights issue by two days, offering shareholders more time to subscribe and clarifying the value of free attaching options.

Percheron Therapeutics has raised $2.3 million through an institutional placement to fully fund its upcoming acute myeloid leukemia clinical trial led by Vanderbilt Health.

Tartana Minerals has lodged a cleansing prospectus to enable ASX quotation of over 129 million options linked to a $4.5 million placement, with exercise price set at 5.5 cents and expiry in April 2029.

Bentley Capital Limited swung back to profitability in FY2026, posting a $255,000 net profit driven mainly by legal settlements and modest investment gains, reversing a prior loss of $878,000.

Keybridge Capital has finally lodged its audited FY2025 Annual Report amid a two-year ASX suspension, with the company set to be delisted on 24 August 2026 due to ongoing financial and compliance concerns.

International Graphite Limited has closed a $4.4 million placement, securing cornerstone investors including Xcelsior Capital to fund expansion of graphite processing operations in Australia and Europe.

Scalare Partners offers 87 bonus options per 100 shares to eligible shareholders alongside piggyback options, aiming to mitigate dilution from upcoming convertible note conversions. Directors plan to exercise their options, with potential capital raised earmarked for working capital.

Andromeda Metals is targeting $3 million through a Share Purchase Plan to fund the next phase of its High Purity Alumina project, including pilot plant optimisation and a Pre-feasibility Study.

Heavy Rare Earths Limited (ASX:HRE) has secured $2.028 million through a placement and entitlement offer to advance drilling programs and a strategic review across its key projects in South Australia and Western Australia.

Zelira Therapeutics has raised nearly US$33 million into its HOPE® 1 special purpose vehicle, valuing the SPV at about US$66 million post-money. The funds will advance FDA regulatory submissions and Phase 1 clinical trials for its autism-targeting cannabinoid drug.

Careteq Limited (ASX: CTQ) has confirmed it will maintain its ASX listing after selling its Embedded Health Solutions subsidiary, shifting its strategic focus entirely to its HMR Referrals platform. The company reported positive operating cash flow in the March quarter and outlined plans to expand its pharmacist and GP networks while exploring AI and adjacent healthcare opportunities.

Yowie Group’s latest quarters reveal falling revenues and shrinking cash reserves, even as new leadership and product launches aim to stabilise the confectionery maker’s turnaround.